Sang Kook Lee;Hyuk Woo Lee;Hwa Jin Chung;Lak Shin Jeong
发明人:
Lak Shin Jeong,Sang Kook Lee,Hwa Jin Chung,Hyuk Woo Lee
申请号：
US13516634
公开号：
US20120322815A1
申请日:
2010.12.16
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, colorectal cancer and prostate cancer, which contains an A3 adenosine receptor agonist, 2-chloro-N6-(3-iodobenzyl)-4′-thioadenosine-5′-N-methyluronamide (thio-Cl-IB-MECA), N6-(3-iodobenzyl)-4′-thioadenosine-5′-N-methyluronamide (thio-IB-MECA), or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the invention is significantly less toxic than conventional A3 adenosine agonists, and thus is useful for prevention or treatment of inflammatory disease. In addition, it more selectively inhibits the growth of androgen receptor-dependent or independent prostate cancer cells than other A3 adenosine receptor agonists and thus is useful for prevention or treatment of colorectal cancer or prostate cancer.
